Ildong Pharmaceutical Co., Ltd.

KOSE:A249420 Stock Report

Market Cap: ₩320.4b

Ildong Pharmaceutical Past Earnings Performance

Past criteria checks 0/6

Ildong Pharmaceutical's earnings have been declining at an average annual rate of -24.5%, while the Pharmaceuticals industry saw earnings growing at 7.3% annually. Revenues have been growing at an average rate of 3.6% per year.

Key information

-24.5%

Earnings growth rate

-22.5%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate3.6%
Return on equity-8.9%
Net Margin-1.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenues Not Telling The Story For Ildong Pharmaceutical Co., Ltd. (KRX:249420) After Shares Rise 33%

Aug 20
Revenues Not Telling The Story For Ildong Pharmaceutical Co., Ltd. (KRX:249420) After Shares Rise 33%

Is Ildong Pharmaceutical (KRX:249420) A Risky Investment?

Aug 12
Is Ildong Pharmaceutical (KRX:249420) A Risky Investment?

If You Had Bought Ildong Pharmaceutical (KRX:249420) Shares A Year Ago You'd Have Earned 18% Returns

Jan 01
If You Had Bought Ildong Pharmaceutical (KRX:249420) Shares A Year Ago You'd Have Earned 18% Returns

Revenue & Expenses Breakdown

How Ildong Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A249420 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24610,282-10,655163,00756,681
30 Jun 24603,864-48,679162,16170,795
31 Mar 24605,800-69,347162,98086,658
31 Dec 23600,758-78,928164,52595,018
30 Sep 23601,608-134,294177,132103,195
30 Jun 23615,710-105,042186,817106,869
31 Mar 23624,122-30,654188,552111,158
31 Dec 22637,714-141,585190,436109,895
30 Sep 22628,484-181,371179,761112,276
30 Jun 22607,365-169,297175,123109,462
31 Mar 22586,512-208,169173,97596,882
31 Dec 21560,132-99,705170,18796,524
30 Sep 21556,191-24,892174,07187,025
30 Jun 21560,494-19,289166,88977,307
31 Mar 21556,360-24,652165,37170,528
31 Dec 20561,845-13,019165,41860,181
30 Sep 20544,875-14,649165,80849,166
30 Jun 20527,837-20,373173,97946,273
31 Mar 20526,985-20,455175,63846,036
31 Dec 19517,468-13,444179,05243,562
30 Sep 19526,6014,344181,53045,728
30 Jun 19525,06312,296184,46943,900
31 Mar 19514,10512,308183,20143,122
31 Dec 18503,90712,721178,73646,458
30 Sep 18486,54019,747174,50844,036
30 Jun 18486,26224,534168,13941,925
31 Mar 18473,01423,666164,48239,432
31 Dec 17460,65119,841164,85933,362
31 Dec 16483,22530,189165,03830,016

Quality Earnings: A249420 is currently unprofitable.

Growing Profit Margin: A249420 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A249420 is unprofitable, and losses have increased over the past 5 years at a rate of 24.5% per year.

Accelerating Growth: Unable to compare A249420's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A249420 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.3%).

Return on Equity

High ROE: A249420 has a negative Return on Equity (-8.9%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 23:29
End of Day Share Price 2025/01/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ildong Pharmaceutical Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Hyerin LeeDAOL Investment & Securities Co., Ltd.
Jae Hoon ShinLS Securities Co., Ltd.